Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
89 studies found for:    heart transplant OR cardiac transplant | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Scleroderma Treatment With Autologous Transplant (STAT) Study
Condition: Systemic Scleroderma
Interventions: Biological: Anti-Thymocyte Globulin;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Plerixafor;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
22 Recruiting Safety Study of Cord Blood Units for Stem Cell Transplants
Conditions: Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome (MDS);   Lymphoma
Intervention: Procedure: Cord Blood Units
23 Recruiting Transplants With Unlicensed Preserved Cord Blood
Conditions: Myelodysplastic Syndrome (MDS);   Hematologic Neoplasms;   Hematologic Diseases;   Severe Aplastic Anemia
Intervention: Procedure: Cord Blood Transplant
24 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
25 Not yet recruiting Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)
Condition: Sickle Cell Disease
Interventions: Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
26 Unknown  Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Procedure: Hematopoietic Cell Transplantation
27 Recruiting Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Conditions: Bronchiolitis Obliterans;   Constructive Bronchiolitis;   Graft Versus Host Disease
Intervention: Drug: Inhaled Cyclosporine Solution
28 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation
29 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
30 Recruiting Screening for Subjects to Participate in Studies of Blood Disorders
Conditions: Bone Marrow Transplant;   Sickle Cell Disease;   G-CSF
Intervention:
31 Recruiting Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Conditions: Bronchiolitis Obliterans;   Graft vs Host Disease
Intervention: Drug: Cyclosporine Inhalation Solution
32 Recruiting Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention: Device: CliniMACS CD34 selection system
33 Unknown  Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: mycophenolate mofetil
34 Recruiting Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome
Conditions: Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions: Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
35 Recruiting Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Campath-1H
36 Recruiting Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Condition: Multiple Myeloma
Interventions: Procedure: Tumor Cell Collection;   Procedure: Autologous Stem Cell Transplant;   Drug: Melphalan;   Procedure: Leukapheresis;   Biological: Myeloma vaccine;   Drug: GM-CSF;   Drug: Lenalidomide
37 Recruiting Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Conditions: Graft vs Host Disease;   Healthy;   Lymphopenia
Intervention: Drug: G-CSF
38 Recruiting Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Condition: Multiple Myeloma
Intervention: Drug: Lenalidomide
39 Recruiting Cell Selection for Bone Marrow Transplants to Prevent Graft-Versus-Host-Disease
Conditions: Graft vs Host Disease;   Hematologic Neoplasm
Intervention:
40 Recruiting Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Conditions: Acute Leukemia;   Myelodysplasia
Interventions: Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years